Viking Therapeutics reported third quarter 2026 results that saw net losses widen significantly as the company aggressively scaled its Phase 3 obesity programs. While revenue remained at zero as expected, the company significantly bolstered its balance sheet through a major capital raise to fund its expanding clinical pipeline.
Key Highlights
- Research and development expenses increased 85% year-over-year to $166.8 million, driven by the launch of the SUNRISE oral Phase 3 trials and ongoing VANQUISH subcutaneous trials.
- Total cash and equivalents reached $960 million as of September 30, 2026, following a successful $575 million public offering of common stock and convertible notes.
- Clinical data for VK2735 maintenance dosing demonstrated robust weight retention, with subjects retaining 82% to 97% of their 16-19% initial weight loss when transitioned to monthly or every-other-week dosing.